190 completed, 46 terminated, 37 recruiting, 15 active not recruiting. 177 Phase 2, 101 Phase 1, 30 Phase 3, 22 Not applicable, 3 Early Phase 1.
Follow Anemia, Refractory, with Excess of Blasts: new trials by email Literature Review of Anemia, Refractory, with Excess of Blasts trials Research Report on Anemia, Refractory, with Excess of Blasts
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patients Luspatercept - Myelodysplasia | Phase 4 | Not yet recruiting | University Hospital, Grenoble | 150 | 2026-11-01 | 2026-09-21 |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms pacritinib - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2026-10-27 | 2026-10-22 |
| Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD) AlloHeme - AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome) | Enrolling by invitation | CareDx | 400 | 2026-09-24 | 2026-10-16 | |
| Dresden MDS Registry With an Accompanying Biomaterial Collection MDS (Myelodysplastic Syndrome), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome | Not yet recruiting | Technische Universität Dresden | 500 | 2026-09-01 | 2026-08-27 | |
| PRAISE-IR Versus CIBMTR Controls ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia) | Not yet recruiting | Miltenyi Biomedicine GmbH | 51 | 2026-07-31 | 2026-07-28 | |
| Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS Ivosidenib - AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Ruijin Hospital | 20 | 2026-05-22 | 2026-05-26 |
| Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms Eltrombopag (ELT) - Myelodysplastic Neoplasm, Myelodysplastic Syndrome | Active not recruiting | Fondazione Italiana Sindromi Mielodisplastiche-ETS | 100 | 2026-05-01 | 2026-09-17 | |
| A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients Allogeneic Hematopoietic Stem Cell Transplantation - Relapsed or Refractory Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome) | Not applicable | Recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-04-01 | 2026-04-15 |
| A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies Non interventional study - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory | Not yet recruiting | ARCE Therapeutics, Inc. | 49 | 2026-03-15 | 2025-12-08 | |
| WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment Axvitiy Ax3 accelorometer - MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia) | Recruiting | University of Oxford | 80 | 2026-02-17 | 2026-04-06 | |
| Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA Romiplostim, Recombinant Human Thrombopoietin - MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA) | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 66 | 2026-01-31 | 2026-04-15 |
| Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation Treosulfan (Treo), Melphalan (Mel), Fludarabine (Flud) - AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Technische Universität Dresden | 220 | 2026-01-21 | 2026-09-02 |
| Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation - Leukemia, Myelodysplasia | Phase 2 | Recruiting | Hannah Choe, MD | 124 | 2026-01-14 | 2026-09-02 |
| Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation RIC regimen - AML (Acute Myeloid Leukemia), MDS/AML | Phase 2 | Not yet recruiting | University Hospital Tuebingen | 27 | 2026-01-01 | 2025-10-09 |
| Luspatercept + Darbepoetin in MDS Luspatercept, Darbeopoetin - MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Yale University | 60 | 2025-12-16 | 2026-09-14 |
| Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS Proton Total Marrow Irradiation - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML | Phase 1 / Phase 2 | Recruiting | Institute of Hematology and Blood Transfusion, Czech Republic | 16 | 2025-11-21 | 2026-04-16 |
| Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation Sulforaphane - ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 36 | 2025-10-22 | 2025-12-30 |
| Haplo-Cord HSCT for AML/MDS haplo-cord HSCT, Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX) - MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia) | Not applicable | Recruiting | Fujian Medical University Union Hospital | 82 | 2025-10-20 | 2026-06-10 |
| PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS PBSS1113 - Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome) | Phase 1 / Phase 2 | Recruiting | Chaser Therapeutics, Inc. | 29 | 2025-09-08 | 2026-08-14 |
Showing 20 of 317. Sign in to see all of them.
Leukemia, Myeloid, Acute (176) · Myelodysplastic Syndromes (169) · Leukemia (142) · Leukemia, Myelomonocytic, Chronic (125) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (115) · Myeloproliferative Disorders (78) · Anemia, Refractory (77) · Congenital Abnormalities (67) · Leukemia, Lymphocytic, Chronic, B-Cell (65) · Lymphoma (60) · Blast Crisis (53) · Lymphoma, Non-Hodgkin (52) · Leukemia, Myeloid, Accelerated Phase (51) · Leukemia, Myeloid, Chronic-Phase (51)
Hemic and Lymphatic Diseases (317) · Bone Marrow Diseases (316) · Anemia (313) · Hematologic Diseases (312) · Neoplasms by Histologic Type (267) · Neoplasms (265) · Anemia, Refractory (240) · Leukemia, Myeloid (239) · Pathologic Processes (197) · Pathological Conditions, Signs and Symptoms (197) · Disease Attributes (194) · Chronic Disease (190) · Immune System Diseases (151) · Myelodysplastic Syndromes (148) · Immunoproliferative Disorders (143)
Cyclophosphamide (64) · fludarabine phosphate (62) · Busulfan (44) · Cyclosporine (41) · Mycophenolic Acid (41) · Peripheral Blood Stem Cell Transplantation (39) · Cytarabine (36) · Whole-Body Irradiation (36) · Antilymphocyte Serum (33) · Filgrastim (26) · Tacrolimus (26) · Methotrexate (25) · fludarabine (24) · Cord Blood Stem Cell Transplantation (22) · Radiotherapy (21)
National Cancer Institute (NCI) (26) · Fred Hutchinson Cancer Center (25) · Masonic Cancer Center, University of Minnesota (13) · Memorial Sloan Kettering Cancer Center (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (11) · M.D. Anderson Cancer Center (9) · Case Comprehensive Cancer Center (8) · European Organisation for Research and Treatment of Cancer - EORTC (7) · National Heart, Lung, and Blood Institute (NHLBI) (7) · University of California, San Francisco (7) · Roswell Park Cancer Institute (5) · Fondazione Italiana Sindromi Mielodisplastiche-ETS (4) · University of Washington (4) · Alliance for Clinical Trials in Oncology (3) · Asan Medical Center (3)
United States (242) · Italy (19) · France (18) · Canada (17) · Germany (16) · United Kingdom (16) · Belgium (11) · China (11) · Australia (10) · Netherlands (9) · Switzerland (9) · Czechia (8) · Spain (8) · Austria (5) · Israel (5)
Brenda Sandmaier (4) · Claudio G. Brunstein, MD, PhD (4) · David Rizzieri, MD (4) · Francis Giles (4) · Thomas G. Martin, M.D. (4) · B. Douglas Smith, MD (3) · Brenda W. Cooper, MD (3) · Johnnie Orozco (3) · Jorge Cortes (3) · Jorge Cortes, MD (3) · Judith E. Karp, MD (3) · Kyoo H. Lee, MD (3) · Mario Sznol, MD (3) · Pamela Becker (3) · Philip L. McCarthy, MD (3)
PMID 18997171, PMID 21715313, PMID 35007144, PMID 10861324, PMID 12114413, PMID 15466923, PMID 15570084, PMID 15817673, PMID 16136166, PMID 16158312, PMID 16278404, PMID 16333838, PMID 16423993, PMID 16651647, PMID 17315155, PMID 17640728, PMID 17910637, PMID 18245545, PMID 18299450, PMID 18769450, PMID 18850014, PMID 19117511, PMID 19139736, PMID 19179301, PMID 19230772, PMID 19286996, PMID 19291085, PMID 19304957, PMID 19528536, PMID 19706886, PMID 19786617, PMID 20056794, PMID 20071660, PMID 20124511, PMID 20413658, PMID 20494931, PMID 20716770, PMID 20858843, PMID 21149672, PMID 21149673, PMID 21403127, PMID 21508125, PMID 21523798, PMID 21681928, PMID 21684344, PMID 21740082, PMID 21816832, PMID 21849481, PMID 22002488, PMID 22009536
P30CA015704 (14), P30CA006973 (10), P30CA043703 (6), U01CA062461 (6), P01CA018029 (5), P01CA044991 (4), P30CA016672 (4), U10CA031946 (4), P01CA015396 (3), U01CA070095 (3), U10CA021115 (3), U10CA032102 (3), N01CM62202 (2), P01CA078902 (2), P30CA008748 (2)